About
Company Overview
Management Team
Board of Directors
Advisors
Partnering
Careers
CBD
Programs
Overview
Graft versus Host Disease (GVHD)
Acute and Chronic Pain
Additional Preclinical Programs
News
Investors
Investor Overview
Press Releases
Company Information
SEDAR Filings
SEC Filings
Stock Information
Corporate Governance
Contact
About
Company Overview
Management Team
Board of Directors
Advisors
Partnering
Careers
CBD
Programs
Overview
Graft versus Host Disease (GVHD)
Acute and Chronic Pain
Additional Preclinical Programs
News
Investors
Investor Overview
Press Releases
Company Information
SEDAR Filings
SEC Filings
Stock Information
Corporate Governance
Contact
Press Releases
Menu
Overview
Press Releases
Company Information
Stock Information
SEC Filings
Corporate Governance
Recent Press Releases
Kalytera Reports First Quarter 2019 Financial Results
May 31, 2019
Kalytera Announces Submission of Patent Application to the U.S. Patent and Trademark Office
May 29, 2019
Kalytera Announces Data Further Elucidating CBD’s Mechanisms of Action in Prevention of GVHD
May 28, 2019
Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products
May 21, 2019
Kalytera Therapeutics Announces Second Closing of Public Offering
May 14, 2019
Kalytera Reports 2018 Financial Results
May 1, 2019
Kalytera Therapeutics Announces Closing of Public Offering
April 26, 2019
View all News and Insights
Browse by Year
2019
2018
2017
2016
2015
